And I don't think anyone, you know, argues with that doctrine. And I don't think the current leadership does. I mean, Marty Macri, the FDA commissioner, has talked about trying to broaden the scope of those policies to try to enable rare disease drugs to get to patients more quickly. This particular drug, though, has attracted scrutiny in the past because of the process that it went through. It's, you know, been sort of written about and maligned. (07:14–07:24)
CLAIM
Asserts that the FDA commissioner is working to broaden policies for faster access to rare disease drugs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
